13.85
price down icon1.91%   -0.27
after-market アフターアワーズ: 13.80 -0.05 -0.36%
loading
前日終値:
$14.12
開ける:
$14.34
24時間の取引高:
629.53K
Relative Volume:
0.69
時価総額:
$393.66M
収益:
$42.35M
当期純損益:
$-78.67M
株価収益率:
-4.9181
EPS:
-2.8161
ネットキャッシュフロー:
$-63.18M
1週間 パフォーマンス:
-13.60%
1か月 パフォーマンス:
-10.30%
6か月 パフォーマンス:
+96.18%
1年 パフォーマンス:
-31.81%
1日の値動き範囲:
Value
$13.30
$14.48
1週間の範囲:
Value
$13.26
$16.55
52週間の値動き範囲:
Value
$5.50
$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
名前
Arcturus Therapeutics Holdings Inc
Name
セクター
Healthcare (1067)
Name
電話
(858) 900-2660
Name
住所
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
111
Name
Twitter
@ArcturusRx
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ARCT icon
ARCT
Arcturus Therapeutics Holdings Inc
13.85 393.66M 42.35M -78.67M -63.18M -2.8161
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-18 開始されました B. Riley Securities Buy
2026-01-23 開始されました Roth Capital Buy
2025-10-24 ダウングレード H.C. Wainwright Buy → Neutral
2025-10-23 ダウングレード Citigroup Buy → Neutral
2025-10-22 ダウングレード Guggenheim Buy → Neutral
2025-09-04 再開されました H.C. Wainwright Buy
2025-05-28 開始されました Scotiabank Sector Outperform
2025-01-28 開始されました BTIG Research Buy
2024-08-12 開始されました Leerink Partners Outperform
2023-12-13 開始されました Canaccord Genuity Buy
2023-07-24 開始されました William Blair Outperform
2023-05-11 アップグレード H.C. Wainwright Neutral → Buy
2022-11-14 再開されました Wells Fargo Overweight
2022-11-10 ダウングレード Robert W. Baird Neutral → Underperform
2022-11-03 アップグレード Citigroup Neutral → Buy
2022-11-02 アップグレード Barclays Underweight → Equal Weight
2022-08-10 ダウングレード Raymond James Mkt Perform → Underperform
2022-07-19 再開されました Cantor Fitzgerald Overweight
2022-05-11 アップグレード Robert W. Baird Underperform → Neutral
2022-04-21 ダウングレード Citigroup Buy → Neutral
2022-01-31 アップグレード Raymond James Underperform → Mkt Perform
2021-08-12 ダウングレード Raymond James Mkt Perform → Underperform
2021-08-11 ダウングレード Goldman Neutral → Sell
2021-08-10 ダウングレード Robert W. Baird Neutral → Underperform
2021-07-02 開始されました Cantor Fitzgerald Overweight
2021-06-25 再開されました Goldman Neutral
2021-06-21 ダウングレード Barclays Equal Weight → Underweight
2021-06-04 再開されました Robert W. Baird Neutral
2021-02-17 ダウングレード B. Riley Securities Neutral → Sell
2021-01-19 ダウングレード B. Riley Securities Buy → Neutral
2021-01-15 ダウングレード B. Riley Securities Buy → Neutral
2021-01-07 開始されました Wells Fargo Overweight
2020-12-29 ダウングレード Barclays Overweight → Equal Weight
2020-12-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-12-29 ダウングレード Raymond James Outperform → Mkt Perform
2020-12-29 ダウングレード Robert W. Baird Outperform → Neutral
2020-12-23 ダウングレード ROTH Capital Buy → Sell
2020-12-08 繰り返されました B. Riley Securities Buy
2020-12-07 繰り返されました B. Riley Securities Buy
2020-10-26 開始されました Barclays Overweight
2020-10-06 開始されました Citigroup Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-30 再開されました ROTH Capital Buy
2020-07-16 開始されました Raymond James Outperform
2020-07-13 開始されました B. Riley FBR Buy
2020-06-09 ダウングレード WBB Securities Buy → Hold
2020-02-11 開始されました Robert W. Baird Outperform
2020-02-07 開始されました Guggenheim Buy
2020-02-06 開始されました Guggenheim Buy
2019-04-05 開始されました H.C. Wainwright Buy
2018-09-20 アップグレード WBB Securities Buy → Strong Buy
2018-01-22 開始されました Chardan Capital Markets Buy
すべてを表示

Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース

pulisher
Sep 26, 2026

(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Sep 26, 2026
pulisher
Sep 25, 2026

A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $41 - Moomoo

Sep 25, 2026
pulisher
Sep 24, 2026

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade - marketscreener.com

Sep 24, 2026
pulisher
Sep 24, 2026

Why Is Arcturus Therapeutics Stock Gaining Thursday? - benzinga.com

Sep 24, 2026
pulisher
Sep 24, 2026

Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

ARCT Upgraded by Citigroup -- Price Target Raised to $20.00 - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

ARCT Looks 565.3% Overvalued on GF Value™ - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ) - Seeking Alpha

Sep 24, 2026
pulisher
Sep 24, 2026

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - benzinga.com

Sep 24, 2026
pulisher
Sep 24, 2026

Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8 - marketscreener.com

Sep 24, 2026
pulisher
Sep 24, 2026

ARCT Maintained by BTIG -- Price Target Lowered to $20 - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Citi Upgrades Arcturus Therapeutics(ARCT.US) to Buy Rating, Raises Target Price to $20 - Moomoo

Sep 24, 2026
pulisher
Sep 24, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics PlatformSlideshow (NASDAQ:ARCT) 2026-09-24 - Seeking Alpha

Sep 24, 2026
pulisher
Sep 23, 2026

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - BioSpace

Sep 23, 2026
pulisher
Sep 23, 2026

Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

ARCT Looks 521.5% Overvalued on GF Value™ - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

Arcturus Showcases Phase 2 ARCT-810 Data, mRNA Advances - TipRanks

Sep 23, 2026
pulisher
Sep 23, 2026

Arcturus Therapeutics Holdings Inc to Host Virtual Presentation Transcript - GuruFocus

Sep 23, 2026
pulisher
Sep 22, 2026

Arcturus Therapeutics Holdings Inc. entered into a definitive agreement to acquire MyNeo NV. - marketscreener.com

Sep 22, 2026
pulisher
Sep 22, 2026

Arcturus Therapeutics (ARCT) Slips 2.11% to $14.38 as Shares Drift Toward Range SupportInside Day Breakout - siam.in

Sep 22, 2026
pulisher
Sep 21, 2026

Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT) - Seeking Alpha

Sep 21, 2026
pulisher
Sep 18, 2026

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform - Yahoo Finance

Sep 18, 2026
pulisher
Sep 17, 2026

ARCT Stock Price and Chart — NASDAQ:ARCT - TradingView

Sep 17, 2026
pulisher
Sep 16, 2026

Trading the Move, Not the Narrative: (ARCT) Edition - Stock Traders Daily

Sep 16, 2026
pulisher
Sep 10, 2026

Arcturus Therapeutics Holdings Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus

Sep 10, 2026
pulisher
Sep 10, 2026

Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa

Sep 10, 2026
pulisher
Sep 10, 2026

Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - Investing.com India

Sep 10, 2026
pulisher
Sep 09, 2026

Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year - Investing.com

Sep 09, 2026
pulisher
Sep 05, 2026

Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily

Sep 05, 2026
pulisher
Sep 04, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026
pulisher
Sep 02, 2026

Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Sep 02, 2026
pulisher
Sep 02, 2026

Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $41 - Moomoo

Sep 02, 2026
pulisher
Sep 01, 2026

Why is Arcturus Therapeutics stock surging today? By Investing.com - Investing.com Canada

Sep 01, 2026
pulisher
Sep 01, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com

Sep 01, 2026
pulisher
Aug 31, 2026

Arcturus Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Aug 31, 2026
pulisher
Aug 30, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Aug 30, 2026
pulisher
Aug 30, 2026

Arcturus Therapeutics (ARCT) Drops 6% as Biotech Sector Headwinds IntensifyFibonacci Fan - dars.gov.et

Aug 30, 2026
pulisher
Aug 28, 2026

Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) - Seeking Alpha

Aug 28, 2026
pulisher
Aug 28, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026
pulisher
Aug 27, 2026

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Aug 27, 2026
pulisher
Aug 25, 2026

Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium - TipRanks

Aug 25, 2026
pulisher
Aug 23, 2026

Arcturus (ARCT) Results Check: EPS Clears the Reported Estimate; Market Response: Shares Finish 22.38% Up for the Current SessionEarnings Power Value - vinanet.vn

Aug 23, 2026
pulisher
Aug 21, 2026

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - Stocktwits

Aug 21, 2026
pulisher
Aug 21, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Aug 21, 2026
pulisher
Aug 20, 2026

ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back - Yahoo Finance

Aug 20, 2026
pulisher
Aug 19, 2026

Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet

Aug 19, 2026
pulisher
Aug 19, 2026

ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade

Aug 19, 2026
pulisher
Aug 19, 2026

ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com

Aug 19, 2026

Arcturus Therapeutics Holdings Inc (ARCT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):